Inspire Medical Systems Inc

Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Inspire Medical Systems Achieves Strong Q1 Performance and Expands Internationally

Inspire Medical Systems reported strong Q1 2023 performance, with significant revenue growth and international expansion. The company's proactive approach to patient experience and market expansion, along with ongoing innovation efforts, positions it for continued success. However, challenges related to the Phillips recall and center utilization require careful management. Despite challenges, the company has opportunities to capitalize on market shifts and technological advancements.

INSP reports strong Q2 earnings, eyes international expansion and new device launch

INSP's Q2 2023 performance reflects robust revenue growth and expansion efforts in the U.S. and international markets. The company is addressing seasonality challenges and focusing on the upcoming launch of the Inspire 5 platform device. INSP remains committed to patient outcomes and physician education to drive therapy adoption.

Inspire Medical Systems Reports Strong Q3 Performance and Expands Coverage

Inspire Medical Systems delivered strong financial performance, despite facing inventory supply issues in Europe. The company's expanded coverage with major payers and focus on long-term growth and profitability position it for future success. However, challenges related to inventory supply and patient capture require careful management.

Inspire Medical Systems reports robust Q4 performance and eyes international expansion

Inspire Medical Systems reported strong Q4 2023 performance, with significant revenue growth and a positive outlook for 2024. The company is focused on expanding its market presence, developing new technology, and addressing potential challenges in international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 2020 Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020.

Inspire Medical Systems, Inc. to Present at the 2020 Stifel Virtual Healthcare Conference

Inspire Medical Systems, Inc. (INSP) CEO Tim Herbert on Q3 2020 Results - Earnings Call Transcript

Shares of Inspire Medical Systems (NYSE:INSP) rose 9.53% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 14.71% over the past year to ($0.39), which beat the estimate of ($0.72).

Recap: Inspire Medical Systems Q3 Earnings

MINNEAPOLIS, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2020.

Inspire Medical Systems, Inc. Announces Third Quarter 2020 Financial Results and Updates 2020 Outlook

Henry Schein

Pacific Biosciences of California

STERIS

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.

Medical Products Earnings Due on Nov 2: STE, HSIC & More

MINNEAPOLIS, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Credit Suisse 29th Annual Healthcare Conference on Tuesday, November 10, 2020.

Inspire Medical Systems, Inc. to Present at the Credit Suisse 29th Annual Healthcare Conference

MINNEAPOLIS, Sept.  24, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2020 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Inspire Medical Systems, Inc. to Report Third Quarter 2020 Financial Results on November 2, 2020

MINNEAPOLIS, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020.

Inspire Medical Systems, Inc. to Present at the Wells Fargo 2020 Virtual Healthcare Conference

MINNEAPOLIS, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that Humana Inc. (“Humana”), one of the leading health plans in the U.S., will provide coverage for the Company’s Inspire therapy, effective August 27, 2020. Humana is a national healthcare company that provides health insurance coverage to approximately 16.7 million individuals in the U.S.

Inspire Medical Systems, Inc. Announces Humana Coverage  for Inspire Therapy

MINNEAPOLIS, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that two additional Blue Cross Blue Shield (“BCBS”) plans will provide coverage for the Company’s Inspire therapy. 

Inspire Medical Systems, Inc. Announces Two Additional Coverage Policies from Blue Cross Blue Shield Healthcare Plans

MINNEAPOLIS, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced that the Australian Therapeutic Goods Administration (“TGA”) has approved Inspire therapy to treat moderate to severe OSA in patients who are unable to benefit from continuous positive airway pressure (“CPAP”).

Inspire Medical Systems, Inc. Announces Regulatory Approval of Inspire Therapy in Australia

Inspire Medical Systems, Inc. (INSP) CEO Tim Herbert on Q2 2020 Results - Earnings Call Transcript

Shares of Inspire Medical Systems (NYSE:INSP) were flat in after-market trading after the company reported Q2 results.

Recap: Inspire Medical Systems Q2 Earnings

MINNEAPOLIS, Aug.  04, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2020.

Inspire Medical Systems, Inc. Announces Second Quarter 2020 Financial Results and Updates 2020 Outlook

Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Inspire Medical Systems (INSP) Q2 Earnings Expected to Decline

MINNEAPOLIS, July  09, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Georgia Garinois-Melenikiotou to the Board of Directors.  Ms. Garinois-Melenikiotou brings a wealth of expertise in global consumer marketing, as well as broad corporate management experience through various senior level roles at multinational companies, including Estée Lauder and Johnson & Johnson.

Inspire Medical Systems, Inc. Announces Appointment of Veteran Consumer Marketing Executive Georgia Garinois-Melenikiotou to its Board of Directors

MINNEAPOLIS, June  16, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Cigna, one of the leading health plans in the United States, will provide coverage for the Company’s Inspire therapy, effective June 15, 2020.  Cigna Corporation is a global health service company that provides health insurance coverage for approximately 16 million members in the U.S.

Inspire Medical Systems, Inc. Announces Cigna Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea

MINNEAPOLIS, June  08, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Phil Ebeling as Chief Operating Officer. Mr. Ebeling is an accomplished global healthcare executive with broad experience in product innovation, strategic planning and business development. In this newly created role at Inspire, he will be responsible for the oversight and leadership of operations, quality assurance, clinical research, regulatory affairs, and business development activities.

Inspire Medical Systems, Inc. Announces Appointment of Medical Technology Industry Veteran Phil Ebeling as Chief Operating Officer

MINNEAPOLIS, June  03, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the introduction of the new Inspire Sleep app.

Inspire Medical Systems, Inc. Introduces Digital Health Tools with Launch of New App

MINNEAPOLIS, May  11, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that Palmetto GBA, LLC, (“Palmetto”) has announced the release date of June 21, 2020, for its final Local Coverage Decision (“LCD”) policy covering Inspire therapy. Palmetto was the only remaining Medicare Administrative Contractor (“MAC”) to have not either issued its final LCD policy or set a release date.

Inspire Medical Systems, Inc. Announces Medicare Policy Release Date of Local Coverage Determination for Sole Remaining Region

Inspire Medical Systems' (INSP) CEO Tim Herbert on Q1 2020 Results - Earnings Call Transcript

Inspire Medical (INSP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Inspire Medical (INSP) This Earnings Season?

MINNEAPOLIS, April  21, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today that the U.S. Food and Drug Administration (“FDA”) has approved an expanded age range for Inspire therapy to include 18-21 year old patients, as compared to the previous minimum age requirement for patients to be 22 years old. Following a detailed review of the clinical evidence and iterative discussions with the FDA, Inspire believes that this is the initial step in the pediatric approval process, with further expansion to lower age groups possible.

Inspire Medical Systems Announces FDA Approval of Expanded Age Range for Inspire Therapy

MINNEAPOLIS, April  16, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:  INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the closing of its public offering of 2,300,000 shares of its common stock, at a public offering price of $58.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 300,000 additional shares. The gross proceeds from the offering are approximately $133.4 million, before deducting the underwriting discounts and commissions and offering expenses payable by Inspire.

Inspire Medical Systems, Inc. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MINNEAPOLIS, April  13, 2020  (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced preliminary unaudited revenue for the quarter ended March 31, 2020, and the withdrawal of its full year 2020 financial guidance issued on February 25, 2020. In addition, Inspire provided an update on the actions it is taking in response to the ongoing global COVID-19 pandemic.

News for Inspire Medical Systems Inc Stock (INSP)